NCT00000231CompletedPhase 2
Buprenorphine Detoxification With Two Types of Treatment. BBD IV
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Locations
- 1
- Primary Endpoint
- Overall treatment outcome
Study Overview
Brief Summary
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Please contact site for information.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall treatment outcome
Retention
Naltrexone consumption
Drug use
Weeks abstinent
Weeks continuous abstinence
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12Opioid-Related DisordersNCT00000230University of Vermont
Completed
Phase 2
Buprenorphine Detox With Two Types of Treatment. BBD II - 11Opioid-Related DisordersNCT00000229University of Vermont
Completed
Phase 2
Buprenorphine Detox With Two Types of Treatment. BBD I - 10Opioid-Related DisordersNCT00000228National Institute on Drug Abuse (NIDA)
Completed
Phase 2
Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22Cocaine-Related DisordersOpioid-Related DisordersNCT00000240University of Vermont
Completed
Phase 4
Buprenorphine Maintenance vs. Detoxification in Prescription Opioid DependenceOpiate DependenceNCT00555425Yale University113